HDAC9 and angioimmunoblastic T-cell lymphoma: Interestingly, although in the relapsed setting, PTCL histology does not seem to significantly impact outcomes when treated with standard chemotherapy, angioimmunoblastic T-cell lymphoma, known for its poor survival rates, appears to benefit most from HDAC inhibitor-based therapies among nodal PTCL subtypes.